Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia

Maike Buchner (), Eugene Park, Huimin Geng, Lars Klemm, Johanna Flach, Emmanuelle Passegué, Hilde Schjerven, Ari Melnick, Elisabeth Paietta, Dragana Kopanja, Pradip Raychaudhuri and Markus Müschen
Additional contact information
Maike Buchner: University of California San Francisco
Eugene Park: University of California San Francisco
Huimin Geng: University of California San Francisco
Lars Klemm: University of California San Francisco
Johanna Flach: The Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California San Francisco
Emmanuelle Passegué: The Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research, University of California San Francisco
Hilde Schjerven: University of California San Francisco
Ari Melnick: Weill Cornell Medical College
Elisabeth Paietta: Montefiore Medical Center, Albert Einstein College of Medicine
Dragana Kopanja: University of Illinois at Chicago
Pradip Raychaudhuri: University of Illinois at Chicago
Markus Müschen: University of California San Francisco

Nature Communications, 2015, vol. 6, issue 1, 1-14

Abstract: Abstract Despite recent advances in the cure rate of acute lymphoblastic leukaemia (ALL), the prognosis for patients with relapsed ALL remains poor. Here we identify FOXM1 as a candidate responsible for an aggressive clinical course. We show that FOXM1 levels peak at the pre-B-cell receptor checkpoint but are dispensable for normal B-cell development. Compared with normal B-cell populations, FOXM1 levels are 2- to 60-fold higher in ALL cells and are predictive of poor outcome in ALL patients. FOXM1 is negatively regulated by FOXO3A, supports cell survival, drug resistance, colony formation and proliferation in vitro, and promotes leukemogenesis in vivo. Two complementary approaches of pharmacological FOXM1 inhibition—(i) FOXM1 transcriptional inactivation using the thiazole antibiotic thiostrepton and (ii) an FOXM1 inhibiting ARF-derived peptide—recapitulate the findings of genetic FOXM1 deletion. Taken together, our data identify FOXM1 as a novel therapeutic target, and demonstrate feasibility of FOXM1 inhibition in ALL.

Date: 2015
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/ncomms7471 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:6:y:2015:i:1:d:10.1038_ncomms7471

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/ncomms7471

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().